You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 481 - 490 of 4911 results
  1. Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Optic Neuritis

    SBC: TRIANGLE THERAPEUTICS INC.            Topic: 100

    PROJECT SUMMARY Optic neuritis (ON) is an acute autoimmune disease caused by immune attack on the myelin that protects the optic nerve leading to vision loss. Steroid treatments accelerate recovery of visual acuity in some patients but have no effect on other visual functions such as contrast sensitivity that are important for activities of daily life. Even with steroid treatments, 13,000 ON patie ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  2. Development of small molecule RPN13 inhibitors for Treatment of Glioblastoma

    SBC: Up Therapeutics LLC            Topic: NCI

    Abstract. Glioblastoma (GBM) is an aggressive and deadly brain cancer with a one year median survival due to the lack of effective targeted treatments. Our goal is to develop a small molecule inhibitor targeting RPN13 protein in the 19S proteasome complex as a new drug for GBM. RPN13 is a proteasome ubiquitin receptor that recognizes ubiquitin-conjugated proteins that are thus tagged for degradati ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  3. Combination of CB101 and radiation therapy in head and neck squamous cell carcinoma

    SBC: Curebiotech, Inc.            Topic: 102

    Curebiotech, Inc., FOA # PA-21-262 Application number 1121483 PROJECT SUMMARYHead and neck squamous cell carcinoma (HNSCC) is the seventh leading cause of cancer-related mortality in the world. Radiation therapy (RT) is routinely used for patients with locoregionally advanced disease. The historical 5-year overall survival rates for locally advanced HNSCC after treatment with surgery, chemotherapy ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  4. Molecular brush-conjugated antisense oligonucleotide as a pan-KRAS depletion agent

    SBC: PACDNA LLC            Topic: NCI

    Project Summary/AbstractMutant forms of KRAS are a key driver in human tumors but remain partially refractory to therapeutic intervention. After over three decades of research, only a single inhibitor (sotorasib) targeting a single mutation (KRASG12C) have reached market. The difficulty for developing small molecule KRAS inhibitors has heightened the importance of alternative methods targeting the ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  5. Development of Host- Oriented Therapeutics Targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NIAID

    The ultimate goal of this Phase I application is to discover and develop host-oriented small molecule compounds targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection. SARS-CoV-2 is a novel coronavirus driving the current global pandemic of severe respiratory syndrome in humans. Antiviral therapeutics are urgently needed to combat infection by SARS-CoV-2 and new variants ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  6. New anti-glioblastoma metabolic compounds with high potential for Blood Brain Barrier penetration

    SBC: WAYPATH PHARMA LLC            Topic: NCI

    Glioblastomas are very aggressive tumors of the central nervous system (CNS) with a median patient survival of about 16 months. Therapeutic options for glioblastoma patients are very limited mostly because the majority of potential anti-cancer drugs do not cross the blood brain barrier (BBB). In addition, recently tested immunotherapies including immune checkpoint inhibitors, tumor vaccines, and a ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  7. Making Connections Thru Music: A Group Music Therapy-Based Intervention for Persons with Dementia

    SBC: HOPEFUL AGING LLC            Topic: NIA

    PROJECT SUMMARY/ABSTRACTHealthcare systems around the world, including within the United States, have long-established shortages of trained caregivers (WHO, 2016; Jones, Liu, Murfield, andamp; Moyle, 2020). The American Health Care Association (2019) states that “the health care system has experienced a shortage of trained caregivers for critical roles for some time.” This scarcity directly im ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  8. Feasibility study of novel hand hygiene formulations against bacterial spore infection

    SBC: CAMELLIX, LLC            Topic: NIAID

    Project Summary: Spore-forming bacterial species, such as various Bacilli and Clostridia, undergo a sporulation process under unfavorable conditions to form dormant spores. These bacterial spores have become a threat to the food industry as they can cause food spoilage and food poisoning. In addition, an opportunistic pathogen, Clostridium difficile (C. difficile), one of the five CDC- listed urge ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  9. Development of miCas9 mediated gene editing therapies for cystic fibrosis

    SBC: GENETOBE INC            Topic: NHLBI

    Project Summary Cystic Fibrosis (CF) is a genetic disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The disease affects multiple organs, with lung disease producing most CF morbidity and mortality. Major progress has been made over the past decade in CF drug development. Greater than 90% patients now benefit from mono or combination therapy of seve ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  10. Imaging Bacterial Infections in Vivo: First in Man Studies

    SBC: Microbial Medical, Inc.            Topic: NIAID

    Project Summary/AbstractInfection is the major complication of virtually all medical devices. It is estimated that 2 million patients acquire a nosocomial infection in the US every year and the CDC estimates that the financial impact of these infections exceeds 5 billion dollars annually. At least half of these infections are directly associated with medical devices. Most commonly, the diagnosis o ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government